Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 24Terminated 10Unknown 7Active not recruiting 3Not yet recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Endocrine 2Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 704Carcinoma, Non-Small-Cell Lung 470Prostatic Neoplasms 420Neoplasms 380Multiple Myeloma 264Colorectal Neoplasms 261Lung Neoplasms 247Neoplasm Metastasis 229Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 189Pancreatic Neoplasms 182Squamous Cell Carcinoma of Head and Neck 163Recurrence 147Carcinoma, Renal Cell 145Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 135Stomach Neoplasms 128Triple Negative Breast Neoplasms 127Brain Neoplasms 124Carcinoma, Hepatocellular 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Carcinoma, Small Cell × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Checkpoint Therapeutics, Inc.

Phase 1 Active not recruiting
272 enrolled 1 FDA
DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡